السوق العالمية للحقن القابلة للارتداء – اتجاهات الصناعة والتوقعات حتى عام 2031

تحليل حجم سوق المحقنات القابلة للارتداء

تستمر سوق المحقنات القابلة للارتداء في النمو مع التقدم التكنولوجي، مما يوفر فوائد كبيرة في توصيل الأدوية. تتيح هذه الأجهزة إدارة مريحة ودقيقة للأدوية، مما يحدث ثورة في رعاية المرضى. يعزز تصميمها المدمج وميزاتها سهلة الاستخدام من قابلية النقل والامتثال، مما يمكن الأفراد الذين يعانون من أمراض مزمنة من إدارة صحتهم بشكل فعال ويمثل تحولًا نموذجيًا في العلاج الطبي. 

تم تقييم حجم سوق المحاقن القابلة للارتداء العالمية بـ 7.27 مليار دولار أمريكي في عام 2023، ومن المتوقع أن يصل إلى 15.69 مليار دولار أمريكي بحلول عام 2031، مع معدل نمو سنوي مركب بنسبة 10.1٪ خلال الفترة المتوقعة من 2024 إلى 2031. يشير هذا إلى أن القيمة السوقية. بالإضافة إلى الرؤى حول سيناريوهات السوق مثل القيمة السوقية ومعدل النمو والتجزئة والتغطية الجغرافية واللاعبين الرئيسيين، تتضمن تقارير السوق التي أعدتها Data Bridge Market Research أيضًا تحليلًا عميقًا للخبراء وعلم الأوبئة للمرضى وتحليل خط الأنابيب وتحليل الأسعار والإطار التنظيمي.

نطاق التقرير وتقسيم السوق

تعريف السوق

Wearable injectors are portable medical devices designed to administer medication through subcutaneous or intramuscular injection. They are worn directly on the body, providing convenience and discretion for patients requiring regular injections, such as those with chronic conditions such as diabetes or autoimmune disorders. These devices offer precise dosing and can improve treatment adherence and patient outcomes.           

Wearable Injectors Market Dynamics

Drivers

• Rise in Chronic Diseases

The surge in chronic diseases such as diabetes, cardiovascular ailments, and autoimmune disorders demands consistent medication administration. Wearable injectors offer a user-friendly approach to delivering these medications, fueling market expansion. For instance, diabetic patients requiring frequent insulin injections find wearable injectors such as Insulet's Omnipod convenient. These devices enable discreet, on-the-go insulin delivery without the hassle of traditional injections, empowering patients to manage their condition effectively while maintaining an active lifestyle.

• Preference for Home Healthcare

The rising preference for home healthcare underscores a shift towards patient-centric approaches. Wearable injectors cater to this trend by empowering patients to self-administer medication conveniently at home. This enhances patient comfort and lowers healthcare expenses linked to hospital visits, aligning with the evolving landscape of self-management and cost-effective healthcare solutions.

Opportunities

• Drug Development Pipeline

The increasing number of biologic drugs, often necessitating subcutaneous administration, drives demand for wearable injectors. Biologics often mandate larger volumes and frequent injections. For instance, monoclonal antibodies such as medications such as monoclonal antibodies, insulin for diabetes management, and growth factors for certain cancers all benefit from wearable injectors, ensuring precise delivery and enhanced patient compliance in long-term treatment regimens.

• Focus on Patient Outcomes

Healthcare providers prioritize patient outcomes and treatment adherence. Wearable injectors, with features such as dose reminders, tracking, and connectivity to healthcare providers, facilitate better compliance. These devices empower patients to manage their medication effectively, improving treatment outcomes.

Restraints/Challenges

• Data Security and Privacy Concerns

Wearable injectors with integrated data connectivity for monitoring raise privacy concerns, necessitating robust cybersecurity measures. Protecting patient data from breaches is paramount, requiring stringent safeguards against unauthorized access or misuse. These measures ensure confidentiality and trust in these medical devices, maintaining patient privacy and safeguarding sensitive health information against potential security threats in the digital healthcare landscape. 

• High Cost of Development

The market faces hurdles due to high initial development, manufacturing, and deployment costs. This may hinder adoption, particularly in less affluent regions or healthcare systems, where budget constraints are prevalent, highlighting the need for cost-effective solutions to improve accessibility and expand the market reach. 

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In 2023, Enable Injections, Inc. forged a partnership with Viridian Therapeutics, Inc., a U.S.-based biotech firm, expanding collaborative efforts
•  In 2023, Tandem Diabetes Care, Inc. finalized the acquisition of AMF Medical SA, known for producing the Sigi Patch Pump, bolstering its portfolio
• In 2022, AbbVie gained US FDA approval for SKYRIZI, an interleukin-23 inhibitor, for treating moderately to severely active Crohn's disease. Administered via subcutaneous injection, it offers patients a self-administration option with an On-Body Injector
• In 2022, Enable Injections secured a USD 215 million funding round to advance enFuse, its subcutaneous drug delivery system. Comprising a wearable delivery disc and a vessel transfer system, enFuse promises enhanced drug delivery
• In 2020, Insulet Corporation, known for its Omnipod Insulin Management System, extended financial aid to its U.S. customers affected by the pandemic. Eligible customers could receive up to a six-month supply of products free of charge, easing financial burdens

Wearable Injectors Market Scope

The market is segmented on the basis of type, therapy, technology, and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• On-Body
• Off-Body

Therapy

• Immuno-Oncology
• Diabetes
• Cardiovascular Diseases
• Parkinson's Disease
• Thalassemia
• Primary Immunodeficiency Disease

Technology

• Spring-based
• Motor-driven

End-Use

• Hospitals
• Clinics
• Homecare
• Others

Wearable Injectors Market Regional Analysis/Insights

The market is analysed and market size insights and trends are provided by country, type, therapy, technology, and end-user as referenced above.

The countries covered in the market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America.

North America is expected to dominate the wearable injectors market, driven by increased chronic disorders, advanced healthcare infrastructure, and easy availability of large-volume injectors. This region leads in adoption, benefiting from accessibility and technological advancements and fostering market growth.

Asia-Pacific has witnessed positive growth in the wearable injectors market, attributed to increased awareness of ultra-large volume devices. Favourable government initiatives for medical devices further propel a market expansion, particularly benefiting the adoption of wearable injectors in the region's healthcare sector.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Wearable Injectors Market Share Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.

Some of the major players operating in the market are:

• BD (U.S.)
• Ypsomed (Switzerland)
• Amgen Inc. (U.S.)
• Subcuject Aps (Denmark)
• Enable Injections (U.S.)
•  Medtronic (Ireland)
• Insulet Corporation (U.S.)
• United Therapeutics Corporation (U.S.)
• CeQur Simplicity (سويسرا)
• شركة جيرشيمر أيه جي (سويسرا)
• شركة ويست للخدمات الصيدلانية المحدودة (الولايات المتحدة)
• سونسيبوز (سويسرا)
• أجهزة توصيل الأدوية Elcam (إسرائيل)
• شركة ريسيفارم ايه بي (المملكة المتحدة)
• مجموعة ستيفاناتو (إيطاليا)
• سوريل ميديكال (إسرائيل)
• شركة Weibel CDS AG (سويسرا)

SKU-68241